{"nctId":"NCT00823836","briefTitle":"Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","startDateStruct":{"date":"2009-03"},"conditions":["Parkinson Disease"],"count":302,"armGroups":[{"label":"ropinirolePR-PR group","type":"EXPERIMENTAL","interventionNames":["Drug: ropinirole PR/XR"]},{"label":"ropiniroleIR-PR group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: ropinirole PR/XR","Drug: ropinirole IR"]}],"interventions":[{"name":"ropinirole PR/XR","otherNames":["ropinirole IR-PR group"]},{"name":"ropinirole IR","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nInclusion criteria at the start of the screening\n\n* Patients who are diagnosed with advanced Parkinson's disease (PD) with severity of the modified Hoehn \\& Yahr criteria Stages II-IV.\n* Subjects receiving a stable dose of L-dopa for at least 4 weeks prior to screening phase and demonstrating lack of control with L-dopa therapy in the following circumstances. Wearing-off phenomena. On-off fluctuations. Delayed-on/No on phenomena. Not adequately controlled on L-dopa\n* QTc\\<450 millisecond (msec) or \\<480msec for patients with Bundle Branch Block - values based on either single ECG values or triplicate electrocardiogram (ECG) averaged QTc values obtained over a brief recording period.\n* Age:20 years or older(at the time of informed written consent)\n* Informed consent: Patients who are able to give informed written consent in person. (i.e. patients who are capable of giving informed written consent on one's own)\n* Sex: either sex. Female of child-bearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the screening visit, agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the following methods of contraception from the screening visit until the end of the follow-up examination. Abstinence. Injectable progestogen. Implants of levonorgestrel. Estrogenic vaginal ring. Percutaneous contraceptive patches. Intrauterine device (IUD) or intrauterine system (IUS) that meets the SOP effectiveness criteria as stated in the product label. Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject. Double barrier method: condom or occlusive cap (diaphragm or cervical / vault caps) plus spermicidal agent (foam /gel / film / cream / suppository)\n* Both inpatient and outpatient status.\n\nInclusion Criteria at the start of the non-inferiority verification phase\n\n-Patients whose Unified Parkinson's Disease Rating Scale (UPDRS) PartIII total (on) scores is 10 points or more at week 0.\n\nExclusion Criteria:\n\n* Late stage advanced subjects demonstrating incapacitating peak dose or biphasic dyskinesia on their stable dose of L-dopa.\n* Patients who present serious physical signs and symptoms other than those of the PD (e.g. cardiac/hepatic/renal disorder and haematopoietic disorder). The severity refers to Grade 3 according to \"the Classification of the Severity of Adverse Experiences (Pharmaceutical affairs bureau/Safety division (PAB/SD) Notification No. 80, dated 29 June 1992).\n* Patients with symptomatic postural hypotension. (e.g. dizziness and syncope).\n* Patients with a current or history of drug abuse or alcoholism.\n* Patients who have received surgical treatment for PD in the past (e.g. pallidectomy, deep brain stimulation).\n* Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study or within 30 days after the last dose of the study drug.\n* Patients with chronic hepatitis typeB and/or type C which is positive of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibody.\n* Patients with a history of drug allergy to ropinirole hydrochloride (HCl).\n* Patients with a current or history of cancer or malignant tumor.\n* Others whom the investigator (subinvestigator) considers ineligible for the study.\n\nExclusion criteria at the start of the non-inferiority verification phase\n\n* Patients with severe dementia (e.g. score 3 or 4 of the UPDRS item 1 (Intellectual Impairment))\n* Patients with current or history of major psychosis (e.g. schizophrenia or psychotic depression) core 3 or 4 of the UPDRS item 2 (thought disorder) or item 3(depression).\n* Patients who have used any dopamine agonist within 4 weeks prior to the non-inferiority verification phase\n* Patients who have been treated with the following drugs at 4 weeks or earlier before the start of the non-inferiority verification phase, and whose treatment regimen of the drug has been changed. Anticholinergic agents: trihexyphenidyl hydrochloride (e.g. Artane®), piroheptine hydrochloride (Trimol®), mazaticol hydrochloride (Pentona®), metixene hydrochloride (Cholinfall®), biperiden hydrochloride (Akineton®), profenamine (Parkin®), amantadine hydrochloride (e.g. Symmetrel®),droxidopa (Dops®), citicoline (e.g. Nicholin®), selegiline hydrochloride (FP®), entacapone, (comutan®) zonisamide, Estrogens: e.g. estriol (e.g. Estriel®), CYP1A2 inhibitors: Ciprofloxacin HCl (e.g. Ciproxan®, enoxacin and fluvoxamine).\n* Patients who have been treated with any other investigational drug within 12 weeks prior to the treatment phase.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week 24) in the Non-Inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of Parkinson's Disease (PD) patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. Participants who withdrew before Week 2 and who had only one observation for the part III total score were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.8","spread":"8.32"},{"groupId":"OG001","value":"-11.0","spread":"7.56"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders on the Japanese UPDRS Part III Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"Thirty percent responders were defined as participants with a 30 percent or greater reduction from Week 0 in the Japanese UPDRS Part III total score. Twenty percent responders were defined as participants with a 20 percent or greater reduction from Week 0 in the Japanese UPDRS Part III total score. On-treatment last observations within the phase were carried forward as FAP values of the phase. FAP values do not include values of Weeks 0, 1, and 2; participants who withdrew before Week 2 and who had only one measurement for the part III total score were not included in the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"78","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.25"},{"groupId":"OG001","value":"-0.3","spread":"1.21"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part II (at \"On\") Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Mean change from Week 0 was calculated as the total score at FAP minus the score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"3.69"},{"groupId":"OG001","value":"-2.9","spread":"4.17"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part II (at \"Off\") Total Score at Week 24 in the Non-Inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. Particpants with only one observation for the part II (at \"Off\") total score were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"4.49"},{"groupId":"OG001","value":"-3.8","spread":"5.15"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.51"},{"groupId":"OG001","value":"-0.2","spread":"1.68"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part I Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.30"},{"groupId":"OG001","value":"1.1","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.34"},{"groupId":"OG001","value":"0.8","spread":"1.50"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part II (at \"On\") Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":"5.51"},{"groupId":"OG001","value":"7.6","spread":"5.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":"5.21"},{"groupId":"OG001","value":"4.6","spread":"5.23"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part II (at \"Off\") Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.6","spread":"8.03"},{"groupId":"OG001","value":"13.1","spread":"6.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.6","spread":"7.24"},{"groupId":"OG001","value":"8.7","spread":"6.39"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part III Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.0","spread":"9.47"},{"groupId":"OG001","value":"24.3","spread":"9.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":"9.91"},{"groupId":"OG001","value":"12.7","spread":"9.39"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part IV Total Score at Week 0 and FAP (up to Week 24) in the Non-inferiority Verification Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":"2.59"},{"groupId":"OG001","value":"2.8","spread":"2.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.25"},{"groupId":"OG001","value":"2.6","spread":"2.49"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders on the Clinical Global Impression-Improvement (CGI-I) at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"The CGI-I assesses the participant's improvement or worsening of PD from Baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Responders are defined as those participants with scores of very much improved or much improved.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63","spread":null},{"groupId":"OG001","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders in Change From Week 0 in Awake Time Spent \"Off\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction on change from Week 0 in Off time (percentage).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders in Percent Change From Week 0 in Awake Time Spent \"Off\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction in percent change from Week 0 in Off time (percentage).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Awake Time Spent \"Off\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 in Off time (actual hours) was calculated as Off time (hours) at FAP minus Off time (hours) at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.88","spread":"3.941"},{"groupId":"OG001","value":"-2.59","spread":"4.691"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Percentage of Awake Time Spent \"Off\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. \"Off\" time is measured as a proportion using the following formula: (Sum of two days off time \\[hours\\]/Sum of two days awake time \\[hours\\]) x 100. Change from Week 0 in Off time is measured using the following formula: Off time (proportion) at FAP minus Off time (proportion) at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.39","spread":"23.600"},{"groupId":"OG001","value":"-16.81","spread":"27.150"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Week 0 in Percentage of Awake Time Spent \"Off\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. \"Off\" time is measured as a proportion using the following formula: (Sum of two days off time \\[hours\\]/Sum of two days awake time \\[hours\\]) x 100. Percent change from Week 0 in Off time (proportion) is measured using the following formula: (Change from Week 0 in Off time \\[proportion\\]/Off time \\[proportion\\] at Week 0) x 100.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.36","spread":"77.250"},{"groupId":"OG001","value":"-40.48","spread":"60.344"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Awake Time Spent \"On\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Mean Change from Week 0 in On time (actual hours) was calculated as On time (hours) at FAP minus On time (hours) at Week 0. Participants who had only one observation for On time were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.65","spread":"3.215"},{"groupId":"OG001","value":"1.35","spread":"3.539"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Percentage of Awake Time Spent \"On\" at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"On\" state is defined as the state at which PD symptoms are well controlled by the drug. \"On\" time is measured as a proportion using the following formula: (Sum of two days On time \\[hours\\]/Sum of two days awake time \\[hours\\]) x 100. Change from Week 0 in On time is measured using the following formula: On time (proportion) at FAP minus On time (proportion) at Week 0. Participants who had only one observation for On time were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.03","spread":"18.634"},{"groupId":"OG001","value":"7.79","spread":"19.895"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Awake Time Spent \"On\" With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Troublesome dyskinesia is defined as dyskinesia that interferes with the participant's daily activity. Mean change from Week 0 in On time with troublesome dyskinesias (actual hours) was calculated as On time with troublesome dyskinesias (hours) at FAP minus On time with troublesome dyskinesias (hours) at Week 0. Participants who had only one observation for On time with troublesome dyskinesias were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"3.886"},{"groupId":"OG001","value":"0.87","spread":"2.311"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Percentage of Awake Time Spent \"On\" With Troublesome Dyskinesias at FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"\"On\" time with troublesome dyskinesias is measured as a proportion using the following formula: (Sum of two days On time with troublesome dyskinesias \\[hours\\]/Sum of two days awake time \\[hours\\]) x 100. Change from Week 0 in On time with troublesome dyskinesias is measured using the following formula: On time with troublesome dyskinesias (proportion) at FAP minus On time with troublesome dyskinesias (proportion) at Week 0. Participants who had only one observation for On time with troublesome dyskinesias were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.61","spread":"24.247"},{"groupId":"OG001","value":"5.39","spread":"14.399"}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at \"On\") at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at \"Off\") at Week 0 and FAP (up to Week 24) in the Non-Inferiority Verification Phase","description":"The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole PR-Ropinirole PR Group","description":"The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 24) was the event, and participants who had completed the phase were censored.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Remaining in the Study on the Indicated Days During the Non-Inferiority Verification Phase in the Ropinirole IR-Ropinirole PR Group","description":"The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 24) was the event, and participants who had completed the phase were censored.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 (Period Baseline) in the Japanese UPDRS Part I Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"0.40"},{"groupId":"OG001","value":"0.1","spread":"0.45"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in the Japanese UPDRS Part II (at \"On\") Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0","spread":"1.37"},{"groupId":"OG001","value":"0.3","spread":"1.77"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in the Japanese UPDRS Part II (at \"Off\") Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"Off\" state is where PD symptoms are not adequately controlled by the drug. Mean change from Week 0 was calculated as the total score at FAP minus the total score at Week 0. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"1.89"},{"groupId":"OG001","value":"-0.4","spread":"2.35"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in the Japanese UPDRS Part III Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"2.81"},{"groupId":"OG001","value":"-0.7","spread":"3.17"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in the Japanese UPDRS Part IV Total Score at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. Mean change from Week 24 was calculated as the total score at FAP minus the total score at Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"0.64"},{"groupId":"OG001","value":"-0.2","spread":"1.04"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part I Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.96"},{"groupId":"OG001","value":"0.6","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.04"},{"groupId":"OG001","value":"0.7","spread":"1.34"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part II (at \"On\") Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"4.59"},{"groupId":"OG001","value":"4.1","spread":"4.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"4.59"},{"groupId":"OG001","value":"4.3","spread":"4.88"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part II (at \"Off\") Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Only participants who had \"off\" state were included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"6.80"},{"groupId":"OG001","value":"7.8","spread":"5.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.5","spread":"7.31"},{"groupId":"OG001","value":"7.5","spread":"5.78"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part III Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. One participant whose observation could not be obtained at Week 24 was not included in the analysis for Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"8.63"},{"groupId":"OG001","value":"12.3","spread":"8.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.7","spread":"8.23"},{"groupId":"OG001","value":"11.3","spread":"8.86"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part IV Total Score at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. One participant whose observation could not be obtained at Week 24 was not included in the analysis for Week 24.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"2.14"},{"groupId":"OG001","value":"2.5","spread":"2.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":"2.17"},{"groupId":"OG001","value":"2.3","spread":"2.32"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in Awake Time Spent \"Off\" at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 24 in Off time (actual hours) was calculated as Off time (hours) at FAP minus Off time (hours) at Week 24. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.07","spread":"2.912"},{"groupId":"OG001","value":"-0.13","spread":"2.005"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in Percentage of Awake Time Spent \"Off\" at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. \"Off\" time is measured as a proportion using the following formula: (Sum of two days off time \\[hours\\]/Sum of two days awake time \\[hours\\]) x 100. Change from Week 24 in Off time is measured using the following formula: Off time (proportion) at FAP minus Off time (proportion) at Week 24. Participants whose observation could not be obtained after Week 24 because of their premature withdrawal or other reasons were not included in the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.97","spread":"16.470"},{"groupId":"OG001","value":"-0.14","spread":"12.913"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 24 in Awake Time Spent \"On\" With Troublesome Dyskinesias at FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"\"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Troublesome dyskinesia is defined as dyskinesia that interferes with the participant's daily activity. Mean change from Week 24 on On time with troublesome dyskinesias (actual hours) was calculated as On time with troublesome dyskinesias (hours) at FAP minus On time with troublesome dyskinesias (hours) at Week 24. Participants who had 0 hour as On time with troublesome dyskinesias at Week 24 were excluded from the analysis.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"3.180"},{"groupId":"OG001","value":"-1.25","spread":"1.831"}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at \"On\") at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"44","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at \"Off\") at Week 24 and FAP (From Week 26 up to Week 32) in the PR/XR Switching Phase","description":"The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Only participants who had \"off\" state were included in the analysis.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole PR-Ropinirole PR Group","description":"The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 32) was the event, and participants who had completed the phase were censored.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Remaining in the Study on the Indicated Days During the PR/XR Switching Phase in the Ropinirole IR-Ropinirole PR Group","description":"The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 32) was the event, and participants who had completed the phase were censored.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders on the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"Thirty percent responders were defined as participants with a 30 percent or greater reduction from Week 0 (Baseline) in the Japanese UPDRS Part III total score. Twenty percent responders were defined as participants with a 20 percent or greater reduction from Week 0 in the Japanese UPDRS Part III total score.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part I Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part II (at \"On\") Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"4.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part II (at \"Off\") Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"3.83"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part III Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.7","spread":"8.23"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in the Japanese UPDRS Part IV Total Score at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications. Mean change from Week 0 was calculated as the total score at Week 54 minus the total score at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.52"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part I Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part I assesses mentation, behavior, and mood on 4 items. Participants receive a score of 0-4 points per item. The maximum total score is 16 points. A higher score indicates more severe mental symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part II (at \"On\") Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"4.57"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":"4.38"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part II (at \"Off\") Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part II assesses activities of daily living on 13 items. Participants receive a score of 0-4 points per item. The maximum total score is 52 points. A higher score indicates more severe PD symptoms. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":"7.40"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":"6.74"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part III Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part III assesses motor examination on 27 items. Participants receive a score of 0-4 points per item. The maximum total score is 108 points. A higher score indicates more severe PD symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6","spread":"8.54"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.9","spread":"8.08"}]}]}]},{"type":"SECONDARY","title":"Japanese UPDRS Part IV Total Score at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Japanese UPDRS assesses the status of PD patients objectively. Part IV assesses complications of therapy on 11 items. Participants receive a score of 0-4 or 0-1 points per item depending on the item. The maximum total score is 23 points. A higher score indicates more severe symptoms of complications.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":"2.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"2.28"}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders on the CGI-I at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The CGI-I assesses the participant's improvement or worsening of PD from baseline with the following eight grades: 0 = Not Assessed, 1 = Very Much Improved, 2 = Much Improved, 3 = Minimally Improved, 4 = No Change, 5 = Minimally Worse, 6 = Much Worse, and 7 = Very Much Worse. Responders are defined as those participants with scores of very much improved or much improved.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders in Change From Week 0 in Awake Time Spent \"Off\" at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction in change from Week 0 in Off time (percentage).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Responders in Percent Change From Week 0 in Awake Time Spent \"Off\" at Week 54 in the Long-term Phase","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Responders were defined as participants with a 20 percent or greater reduction on percent change from Week 0 in Off time (percentage).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Awake Time Spent \"Off\" at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. Mean change from Week 0 in Off time (actual hours) was calculated as Off time (hours) at Week 54 minus Off time (hours) at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.87","spread":"3.642"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Percentage of Awake Time Spent \"Off\" at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"\"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug. \"Off\" time is measured as a proportion using the following formula: (Sum of two days off time \\[hours\\]/Sum of two days awake time \\[hours\\]) x 100. Change from Week 0 in Off time is measured using the following formula: Off time (proportion) at Week 54 minus Off time (proportion) at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.55","spread":"23.038"}]}]}]},{"type":"SECONDARY","title":"Mean Change From Week 0 in Awake Time Spent \"On\" With Troublesome Dyskinesias at Week 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"\"On\" state is defined as the state at which PD symptoms are well controlled by the drug. Troublesome dyskinesia is defined as dyskinesia that interferes with the participant's daily activity. Mean change from Week 0 in On time with troublesome dyskinesias (actual hours) was calculated as On time with troublesome dyskinesias (hours) at Week 54 minus On time with troublesome dyskinesias (hours) at Week 0.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.33","spread":"0.629"}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at \"On\") at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. \"On\" state is defined as the state at which PD symptoms are well controlled by the drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants at Each Stage of the Modified Hoehn & Yahr Severity of Illness (at \"Off\") at Weeks 0 and 54 in the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The Modified Hoehn \\& Yahr criteria are measured on the following 8-point scale for disease severity: 0, No signs of disease; 1, Unilateral disease; 1.5, Unilateral plus axial involvement; 2, Bilateral disease; 2.5, Mild bilateral disease; 3, Mild to moderate bilateral disease; 4, Severe disability; and 5, Wheelchair bound or bedridden unless aided. \"Off\" state is defined as the state at which PD symptoms are not adequately controlled by the drug.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Remaining in the Study on the Indicated Days During the Long-term Phase in the Ropinirole PR-Ropinirole PR Group","description":"The percentage of participants remaining in the study was presented by Kaplan-Meier method, where premature discontinuation (i.e., withdrawal before Week 54) was the event, and participants who had completed the study were censored.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":156},"commonTop":["Nasopharyngitis","Nausea","Somnolence","Dyskinesia","Constipation"]}}}